Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases.
暂无分享,去创建一个
U. Eriksson | S. Heymans | Y. Adler | C. Basso | C. Rapezzi | M. Maurer | E. González-López | P. García-Pavía | G. Merlini | M. Fontana | A. Caforio | A. Pantazis | A. Linhart | M. Arad | A. Kristen | S. Pankuweit | J. Gillmore | T. Damy | M. Grogan | A. Brucato | M. Imazio | A. Rigopoulos | I. Kindermann | I. Burazor | P. García‐Pavía | E. Gonzalez-Lopez
[1] P. Elliott,et al. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT. , 2020, JACC. Heart failure.
[2] F. Domínguez,et al. Transthyretin amyloid cardiomyopathy. , 2020, Medicina clinica.
[3] M. Maurer,et al. Systemic Amyloidosis due to Monoclonal Immunoglobulins: Cardiac Involvement. , 2020, Hematology/oncology clinics of North America.
[4] A. Petrie,et al. Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage , 2020, ESC heart failure.
[5] M. Maurer,et al. Diuretic Dose and NYHA Functional Class Are Independent Predictors of Mortality in Patients With Transthyretin Cardiac Amyloidosis , 2020, JACC. CardioOncology.
[6] G. Lin,et al. The Challenges in Chemotherapy and Stem Cell Transplantation for Light-Chain Amyloidosis. , 2020, The Canadian journal of cardiology.
[7] A. Masri,et al. Hot hearts on bone scintigraphy are not all amyloidosis: hydroxychloroquine-induced restrictive cardiomyopathy , 2020, European heart journal.
[8] J. A. López,et al. Perfil clínico y evolución de la amiloidosis cardiaca en un centro español de referencia , 2020 .
[9] D. Kuypers,et al. Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients , 2020, Kidney international reports.
[10] G. Pontone,et al. Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis. , 2019, JACC. Cardiovascular imaging.
[11] C. Rapezzi,et al. Assessment of patients with hereditary transthyretin amyloidosis – understanding the impact of management and disease progression , 2019, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[12] M. Maurer,et al. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.
[13] Brian Lilleness,et al. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. , 2019, Blood.
[14] D. Eisenberg,et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee , 2018, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[15] Sanjiv J. Shah,et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.
[16] A. Petrie,et al. A new staging system for cardiac transthyretin amyloidosis , 2018, European heart journal.
[17] S. Solomon,et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.
[18] S. Solomon,et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.
[19] M. Leon,et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement , 2017, European heart journal.
[20] P. Elliott,et al. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis , 2017, Circulation.
[21] A. Dispenzieri,et al. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. , 2016, Journal of the American College of Cardiology.
[22] P. García-Pavía,et al. Analysis of diagnostic and therapeutic strategies in advanced cardiac light-chain amyloidosis. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[23] G. Merlini,et al. What is new in diagnosis and management of light chain amyloidosis? , 2016, Blood.
[24] A. Hagège,et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. , 2016, European heart journal.
[25] James C Moon,et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.
[26] J. Maleszewski. Cardiac amyloidosis: pathology, nomenclature, and typing. , 2015, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[27] E. González-López,et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. , 2015, European heart journal.
[28] D. Dingli,et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] G. Merlini,et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. , 2009, Clinical chemistry.